Literature DB >> 22065114

Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas.

Hector Guadalajara1, Dolores Herreros, Paloma De-La-Quintana, Jacobo Trebol, Mariano Garcia-Arranz, Damian Garcia-Olmo.   

Abstract

PURPOSE: In patients with perianal fistulas, administration of adult stem cells (ASCs) derived from liposuction samples has proved a promising technique in a preceding phase II trial. We aimed to extend follow-up of these patients with this retrospective study.
METHOD: Patients who had received at least one dose of treatment (ASCs plus fibrin glue or fibrin glue alone) were included. Adverse events notified since the end of the phase II study were recorded. Clinical and magnetic resonance imaging (MRI) criteria were used to determine whether recurrence of the healed fistula had occurred.
RESULTS: Data were available for 21 out of 24 patients treated with ASCs plus fibrin glue and 13 out of 25 patients treated with fibrin glue in the phase II study. Follow-up lasted a mean of 38.0 and 42.6 months, respectively. Two adverse events unrelated to the original treatment were reported, one in each group. There were no reports of anal incontinence associated with the procedure. Of the 12 patients treated with ASCs plus fibrin glue who were included in the retrospective follow-up in the complete closure group, only 7 remained free of recurrence. MRI was done in 31 patients. No relationship was detected between MRI results and the clinical fistula status, independent of the treatment received.
CONCLUSIONS: Long-term follow-up reaffirmed the very good safety profile of the treatment. Nevertheless, a low proportion of the stem cell-treated patients with closure after the procedure remained free of recurrence after more than 3 years of follow-up.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22065114     DOI: 10.1007/s00384-011-1350-1

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  16 in total

1.  Infliximab for the treatment of fistulas in patients with Crohn's disease.

Authors:  D H Present; P Rutgeerts; S Targan; S B Hanauer; L Mayer; R A van Hogezand; D K Podolsky; B E Sands; T Braakman; K L DeWoody; T F Schaible; S J van Deventer
Journal:  N Engl J Med       Date:  1999-05-06       Impact factor: 91.245

2.  Safety of infliximab: primum non nocere. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients.

Authors:  Mansour A Parsi; Bret A Lashner
Journal:  Inflamm Bowel Dis       Date:  2004-07       Impact factor: 5.325

3.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

4.  A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation.

Authors:  Damián García-Olmo; Mariano García-Arranz; Dolores Herreros; Isabel Pascual; Concepción Peiro; José Antonio Rodríguez-Montes
Journal:  Dis Colon Rectum       Date:  2005-07       Impact factor: 4.585

Review 5.  Which method is best for imaging of perianal fistula?

Authors:  Vikram A Sahni; Rosemina Ahmad; David Burling
Journal:  Abdom Imaging       Date:  2008 Jan-Feb

6.  A randomized, controlled trial of fibrin glue vs. conventional treatment for anal fistula.

Authors:  Ian Lindsey; M M Smilgin-Humphreys; Chris Cunningham; Neil J M Mortensen; Bruce D George
Journal:  Dis Colon Rectum       Date:  2002-12       Impact factor: 4.585

7.  Repair of fistulas-in-ano using fibrin adhesive: long-term follow-up.

Authors:  J R Cintron; J J Park; C P Orsay; R K Pearl; R L Nelson; J H Sone; R Song; H Abcarian
Journal:  Dis Colon Rectum       Date:  2000-07       Impact factor: 4.585

Review 8.  Management of internal fistulas in Crohn's disease.

Authors:  Cynthia Levy; William J Tremaine
Journal:  Inflamm Bowel Dis       Date:  2002-03       Impact factor: 5.325

9.  Long-term functional outcome and risk factors for recurrence after surgical treatment for low and high perianal fistulas of cryptoglandular origin.

Authors:  Paul J van Koperen; Jan Wind; Willem A Bemelman; Roel Bakx; Johannes B Reitsma; J Frederik M Slors
Journal:  Dis Colon Rectum       Date:  2008-07-15       Impact factor: 4.585

10.  Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn's disease.

Authors:  David Tougeron; Guillaume Savoye; Céline Savoye-Collet; Edith Koning; Francis Michot; Eric Lerebours
Journal:  Dig Dis Sci       Date:  2008-11-12       Impact factor: 3.199

View more
  54 in total

1.  Fistula tract curettage and the use of biological dermal plugs improve high transsphincteric fistula healing in an animal model.

Authors:  Cigdem Benlice; Merve Yildiz; Semih Baghaki; Ilknur Erguner; Deniz Cebi Olgun; Sebnem Batur; Sibel Erdamar; Pinar Ambarcioglu; Ismail Hamzaoglu; Tayfun Karahasanoglu; Bilgi Baca
Journal:  Int J Colorectal Dis       Date:  2015-08-27       Impact factor: 2.571

Review 2.  Useful strategies to prevent severe stricture after endoscopic submucosal dissection for superficial esophageal neoplasm.

Authors:  Kaname Uno; Katsunori Iijima; Tomoyuki Koike; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

Review 3.  Modern management of anal fistula.

Authors:  Elsa Limura; Pasquale Giordano
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

Review 4.  [Regenerative therapy approaches in plastic surgery].

Authors:  J W Kuhbier; K Reimers; C Radtke; P M Vogt
Journal:  Chirurg       Date:  2015-03       Impact factor: 0.955

5.  The clinical efficacy of stem cell therapy for complex perianal fistulas: a meta-analysis.

Authors:  S Choi; B G Jeon; G Chae; S-J Lee
Journal:  Tech Coloproctol       Date:  2019-05-02       Impact factor: 3.781

6.  Long-term results of adipose-derived stem cell therapy for the treatment of Crohn's fistula.

Authors:  Yong Beom Cho; Kyu Joo Park; Sang Nam Yoon; Kee Ho Song; Do Sun Kim; Sang Hun Jung; Mihyung Kim; Hee Young Jeong; Chang Sik Yu
Journal:  Stem Cells Transl Med       Date:  2015-03-31       Impact factor: 6.940

7.  Treatment of Crohn's-Related Rectovaginal Fistula With Allogeneic Expanded-Adipose Derived Stem Cells: A Phase I-IIa Clinical Trial.

Authors:  Mariano García-Arranz; Maria Dolores Herreros; Carolina González-Gómez; Paloma de la Quintana; Héctor Guadalajara; Tihomir Georgiev-Hristov; Jacobo Trébol; Damián Garcia-Olmo
Journal:  Stem Cells Transl Med       Date:  2016-07-13       Impact factor: 6.940

Review 8.  Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): Crohn's disease.

Authors:  G Pellino; D S Keller; G M Sampietro; I Angriman; M Carvello; V Celentano; F Colombo; F Di Candido; S Laureti; G Luglio; G Poggioli; M Rottoli; S Scaringi; G Sciaudone; G Sica; L Sofo; S Leone; S Danese; A Spinelli; G Delaini; F Selvaggi
Journal:  Tech Coloproctol       Date:  2020-03-14       Impact factor: 3.781

9.  Conditioned mesenchymal stem cells produce pleiotropic gut trophic factors.

Authors:  Shuhei Watanabe; Yoshiaki Arimura; Kanna Nagaishi; Hiroyuki Isshiki; Kei Onodera; Masanao Nasuno; Kentaro Yamashita; Masashi Idogawa; Yasuyoshi Naishiro; Masaki Murata; Yasushi Adachi; Mineko Fujimiya; Kohzoh Imai; Yasuhisa Shinomura
Journal:  J Gastroenterol       Date:  2013-11-12       Impact factor: 7.527

Review 10.  Therapy with stem cells in inflammatory bowel disease.

Authors:  María Del Pilar Martínez-Montiel; Gonzalo Jesús Gómez-Gómez; Ana Isabel Flores
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.